Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 214-224

  Coleman, David T ^a   Bigelow, Rebecca ^a   Cardelli, James A ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C 75; EPIGALLOCATECHIN GALLATE; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; LUTEOLIN; PALMITIC ACID; PROTEASOME; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL SURFACE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYMATIC DEGRADATION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INCUBATION TIME; LIPID RAFT; LYSOSOME; MALE; MOLECULAR MIMICRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; FLAVONOIDS; HEPATOCYTE GROWTH FACTOR; HUMANS; LUTEOLIN; LYSOSOMES; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RNA INTERFERENCE;

EID: 58149492131     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0722     Document Type: Article

References (45)

1. Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
2. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
3. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
4. Gentile A, Trusolino L, Comoglio P. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27:85-94.
5. Lengyel EDP, Resau JH, Gauger K, et al. C-Met overexpression in nodepositive breast cancer identifies patients with poor clinical outcome independent of HER2/neu. Int J Cancer 2005;113:678-82.
6. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the Met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;94:11445-50.
7. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-7.
8. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96.
9. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
10. Erdman JW, Jr., Balentine D, Arab L, et al. Flavonoids and heart health. Proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. J Nutr 2007;137:718S-37.
11. Surh Y-J. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
12. Adachi S, Nagao T, Ingolfsson HI, et al. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 2007;67:6493-501.
13. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77.
14. Wang HQ, Altomare DA, Skele KL, et al. Positive feedback regulation between AKTactiv ation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005;24:3574-82.
15. Swinnen JV, Van Veldhoven PP, Timmermans L, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003;302:898-903.
16. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 2005;280:5636-45.
17. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 1996;20:933-56.
18. Bigelow RLH, Cardelli JA. The green tea catechins, (-)-epigallocatechin- 3-gallate (EGCG) and (-)-epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 2006;25:1922-30.
19. Briaud I, Harmon JS, Kelpe CL, Segu VBG, Poitout V. Lipotoxicity of the pancreatic h-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. Diabetes 2001;50:315-21.
20. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cellmotility. Nat Rev Mol Cell Biol 2005;6:56-68.
21. Stambolic V, Suzuki A, de la Pompa JL, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998;95:29-39.
22. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-6.
23. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 2000;97:3450-4.
24. Graff JR, Konicek BW, Carter JH, Marcusson EG. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008;68:631-4.
25. Abella JV, Peschard P, Naujokas MA, et al. Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol Cell Biol 2005;25:9632-45.
26. Hammond DE, Urbe S, Vande Woude GF, Clague MJ. Downregulation of MET, the receptor for hepatocyte growth factor. Oncogene 2001;20:2761-70.
27. Kermorgant S, Zicha D, Parker PJ. Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-Met. J Biol Chem 2003;278:28921-9.
28. Hoffmann KM, Tapia JA, Berna MJ, et al. Gastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanism. J Biol Chem 2006;281:37705-19.
29. Jeffers M, Taylor G, Weidner K, Omura S, Vande Woude G. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol Cell Biol 1997;17:799-808.
30. liShimizu M, Deguchi A, Lim JTE, Moriwaki H, Kopelovich L, Weinstein IB. (-)-Epigallocatechin gallate and polyphenol E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005;11:2735-46.
31. Lee W-J, Wu L-F, Chen W-K, Wang C-J, Tseng T-H. Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem Biol Int 2006;160:123-33.
32. Hendriks JJA, Alblas J, van der Pol SMA, van Tol EAF, Dijkstra CD, de Vries HE. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med 2004;200:1667-72.
33. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science 2003;302:1704-9.
34. Agullo G, Gamet-Payrastre L, Manenti S, et al. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 1997;53:1649-57.
35. Way T-D, Kao M-C, Lin J-K. Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells. FEBS Lett 2005;579:145-52.
36. WAF1/CIP1 expression with rapamycin. Mol Cancer Ther 2007;6:2127-38.
37. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 1953;13:27-9.
38. Huo H, Guo X, Hong S, Jiang M, Liu X, Liao K. Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-1 preadipocyte differentiation induction. J Biol Chem 2003;278:11561-9.
39. Wang L, Zhao YF, Li YL, Xu YF, Xia Q, Ma KL. Effects of lipid rafts on signal transmembrane transduction mediated by c-Met. Zhonghua Gan Zang Bing Za Zhi 2008;16:449-52.
40. Pike LJ. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim Biophys Acta 2005;1746:260-73.
41. Nath D, Williamson N, Jarvis R, Murphy G. Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase. J Cell Sci 2001;114:1213-20.
42. Way T-D, Kao M-C, Lin J-K. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 2004;279:4479-89.
43. Vazquez-Martin A, Colomer R, Brunet J, Menendez JA. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptintrade mark) by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol 2007;31:769-76.
44. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A 2004;101:10715-20.
45. Bandyopadhyay S, Pai SK, Watabe M, et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 2005;24:5389-95.